The deep dive · NASDAQ: MLYS · Read November 3, 2026

Mineralys Therapeutics

A fully remote Pennsylvania drug developer with one blood pressure pill, lorundrostat, an FDA decision due December 22, and a sales force being hired before a rival got there first.

Q2 2026 results release, Aug 11, 2026
Revenue
$0 no sales of any kind yet; lorundrostat is still under FDA review.
Cash
$661.4M cash and investments at June 30, 2026, said to last into 2028.
Debt
$100M drawn from a loan of up to $500M at about 9.9%, due 2031.
Watch
Dec 22 FDA target date to decide on lorundrostat for hypertension.
AI
Not claimed its FY2025 10-K never mentions artificial intelligence.
Hiring
40 of 40 open postings tagged US Remote; 30 are field sales or medical roles tied to a region.
Listings
28 → 34 remote listings since Oct 10.
01 · The business

Every dollar so far came from investors and lenders.

Mineralys has never sold anything. It spends on trials and now on a launch team, paid for by share sales ($578M in 2025 alone) and a new loan. Income starts only if the FDA approves lorundrostat, its single drug.

10-Q Q2 2026 (filed Aug 11, 2026); 10-K FY2025 cash flow
The moat, in three parts
  1. 1
    Two pivotal trials already in the FDA file
    Launch-HTN (1,083 people) cut systolic pressure 9.1 mmHg more than placebo at week 6; Advance-HTN (285 people) met its 24-hour goal.
    10-K FY2025 (filed Mar 12, 2026)
  2. 2
    It now owns the drug outright
    Tanabe assigned the lorundrostat patents to Mineralys on Oct 27, 2026, and royalties on sales were cancelled in June. Milestones of up to $255M remain.
    8-K, Tanabe termination agreement (filed Oct 29, 2026)
  3. 3
    Patent cover into the 2040s
    16 patent families, with nominal expiry from 2035 to about 2046, before any extensions.
    10-K FY2025 (filed Mar 12, 2026)
02 · The turn

Still losing money: $171 million in FY2025.

Revenue
Money coming in, per fiscal year
Operating profit
What is left after running the business
10-K FY2025 statement of operations; FY2023 from 10-K FY2024 (R5)
The balance sheet

Plenty of cash for a launch, but the loan has teeth: it can come due in June 2028 if lorundrostat is not approved by Sept 30, 2027, and from 2028 it requires minimum yearly sales.

$100Mof debt against $661.4M of cash and investments
$100M
senior secured term loan, tranche A (principal)
10-Q Q2 2026 (filed Aug 11, 2026), debt note
The other half · Members

The rest of Mineralys Therapeutics, for members.

The fine print, who gets paid most, where it looks headed and our calls. Free for 3 days, then $9 a month.

5 quick questions, then your matches. No card.
  1. 03

    What the filings say, and what we think it means.

    9 flags, each with our read

  2. 04

    Sales is paid 6% over market.

    Posted pay against the market, 1 team

  3. 05 · 06

    How Mineralys Therapeutics uses AI, and what its hiring says.

  4. 07

    Your view of the next year, in a share price.

  5. 08

    The signals, and which way they push.

    5 signals

  6. 09

    Where Mineralys Therapeutics ends up, if we had to bet.

    5 predictions, with odds

Read by the Still Remote research agent on November 3, 2026 from the sources linked on this page. Facts and scenarios only, not investment advice.